Is NAD+ Legal in Europe? Supplement vs Research Use (2026)
Is NAD+ legal in Europe? The honest answer splits along precursor vs coenzyme. NR is an authorised novel food; NMN is not; NAD+ itself is supplied as a research reagent (RUO). Verified EU sources, no legal advice.
There is no single legality for "NAD+ in Europe" — the question splits along three different things people mean. (1) NAD+ precursors as supplements: nicotinamide riboside (NR) chloride is an authorised novel food in the EU, included in the Union list and permitted in food supplements for the general adult population at up to 300 mg/day; (2) NMN (a different precursor) is treated as a novel food but is not authorised — its applications are still ongoing, so it cannot lawfully be sold as a food supplement in the EU until and unless authorised; (3) NAD+ itself, the intact coenzyme, is not an approved medicine and is supplied by Condor Research strictly as a Research Use Only (RUO) reference material — not a food, not a supplement, not a medicine. "Legal" therefore depends entirely on which molecule, and for what use.
Search “is NAD+ legal in Europe” and you will collect three confident, contradictory answers. They contradict each other because they are quietly answering three different questions. “NAD+” on a longevity podcast usually means a precursor pill; “NAD+” on a chemistry datasheet means the intact coenzyme; and EU law treats a food supplement, a medicine, and a research reagent as three separate worlds with three separate rulebooks. The molecule does not have a legal status. The use does.
Which “NAD+” are we actually talking about?
Before any regulation can apply, you have to pin down the noun. In the longevity conversation, people rarely mean NAD+ itself. They usually mean a precursor — a smaller molecule the body can convert toward NAD+ — most often nicotinamide riboside (NR) or β-nicotinamide mononucleotide (NMN). NAD+ (nicotinamide adenine dinucleotide) is the finished coenzyme one or more enzymatic steps downstream: a large, charged dinucleotide that functions as a central electron carrier and as a consumed substrate for signalling enzymes such as the sirtuins and CD38.1 Our explainer on what NAD+ is walks through the chemistry; the legal point is simpler. NR, NMN and NAD+ are different molecules, and EU law does not treat them as one.
Are NAD+ precursors legal as supplements in the EU?
This is where the answer becomes specific — and where the precursors part ways. The relevant frame is the EU Novel Food regime under Regulation (EU) 2015/2283, which requires that any food not used for human consumption to a significant degree in the EU before 15 May 1997 be authorised before it can be placed on the market.2 Authorised novel foods are entered on a single Union list, established by Commission Implementing Regulation (EU) 2017/2470.3
Nicotinamide riboside (NR) chloride has cleared that gate. Following an EFSA safety opinion, Commission Implementing Regulation (EU) 2020/16 of 10 January 2020 authorised NR chloride as a novel food and added it to the Union list, permitting its use as a source of niacin in food supplements for the general adult population at a maximum level of 300 mg/day.45 For NR, the European answer to “is it legal as a supplement” is a documented yes, within those limits.
Two NAD+ precursors, one authorised as a food supplement and one not. The molecule on the label decides the legal answer — not the word “NAD+” in the marketing.
Where does NMN stand?
Differently, and this is the part most marketing pages blur. NMN is also treated as a novel food in the EU — meaning it falls under the same pre-market authorisation requirement — but it has not been authorised. NMN does not appear on the Union list of authorised novel foods, and the relevant applications remain ongoing in the EU process.6 The practical consequence is precise: until and unless NMN is authorised, it cannot lawfully be placed on the EU market as a food or food supplement.2 That is not the same as the substance being “banned.” It is the difference between a compound that has passed the food-authorisation gate (NR) and one still standing in front of it (NMN). Anyone selling NMN to EU consumers as a supplement is making a claim the Union list does not currently support.
The Commission Implementing Regulation that authorised nicotinamide riboside (NR) chloride as a novel food and added it to the Union list — the food-authorisation gate NR has cleared and NMN has not.4
So what is NAD+ itself — and what does Condor Research supply?
NAD+, the intact coenzyme, is the third case, and it is the one that matters for a research supplier. NAD+ is not on the Union list of authorised novel foods, and it is not an approved medicine: it has no marketing authorisation from the European Medicines Agency or any member state, so there is no lawful route to supply or use it as a medicinal product in the Union.3 What Condor Research supplies is neither a food nor a medicine. It is a research reference material, sold strictly Research Use Only (RUO) for in-vitro and laboratory work.7 That status is not a loophole; it is a different regime. A reagent is, by definition, not placed on the market for human consumption, which is exactly why it sits outside the Novel Food framework that governs supplements. The line is intent and presentation: the moment a material is offered, labelled, or described for human consumption, it leaves reagent territory and falls under the food or medicines regime it has not qualified for.2
| Form of “NAD+” | EU regulatory frame | Status |
|---|---|---|
| Nicotinamide riboside (NR) chloride — precursor | Novel Food (Reg. 2015/2283; Union list 2017/2470) | Authorised novel food; up to 300 mg/day in supplements for adults4 |
| NMN (β-nicotinamide mononucleotide) — precursor | Novel Food (Reg. 2015/2283) | Treated as novel food; NOT authorised — applications ongoing; not lawful as an EU supplement at present6 |
| NAD+ — intact coenzyme | Outside food/medicines regimes when sold RUO | Not an authorised novel food; not an approved medicine; supplied as a Research Use Only reagent37 |
Three molecules, three answers. “NAD+ in Europe” has no single legal status — the frame is set by which compound and for what intended use.
What does the human evidence actually say?
It is worth being precise, because the legal picture and the evidence picture are routinely conflated. The preclinical base for NAD+ biology is substantial: reviews frame NAD+ as a metabolic hub whose age-related decline intersects with multiple cellular hallmarks of ageing,1 and a landmark mouse study reported that long-term NMN administration was associated with changes in energy metabolism and other physiological endpoints in ageing animals.8 The human base is thinner and more cautious. An early study reported that single oral NMN doses were tolerated in healthy men and altered nicotinamide-metabolite levels,9 and a randomised trial reported increased muscle insulin sensitivity in prediabetic women.10 But a systematic review and meta-analysis of randomised trials found that effects on several functional endpoints were limited and inconsistent, while tolerability was generally good.11 In short: rich animal mechanism, early and unsettled human data. None of these studies establishes efficacy or safety for human use, and none changes the regulatory status above. They are reported here strictly as observations from the published literature.
The purity benchmark Condor Research applies to its NAD+ reference material — characterised by HPLC, identity confirmed by mass spectrometry, and tested by an independent EU laboratory in Czechia, with a certificate of analysis per lot.7
What are the honest limits of this map?
Several, and naming them is the point of writing it conservatively. First, this is not legal advice. The Novel Food framework is EU-wide, but enforcement, national supplement rules, and how a given member state handles a particular compound can differ, and only qualified counsel in your own jurisdiction can tell you what applies to you.2 Second, the picture moves. Novel Food authorisations and applications are live processes; NMN’s status in particular could change if an application is authorised, so any snapshot ages — always check the current Union list before relying on it.36 Third, an authorisation governs a food use; it says nothing about whether a given vial actually contains what its label claims. That gap — between what the law permits and what a batch contains — is where a real certificate of analysis does the work no regulation can.7
That is the through-line of everything Condor Research supplies. Our NAD+ is a research reference material for in-vitro and laboratory work, sold strictly Research Use Only — not a food, not a food supplement, not a medicine, and not for human or veterinary use. The regulatory map around NAD+ precursors in Europe is genuinely uneven and genuinely in motion, and we will not pretend otherwise; what does not move is the obligation to know exactly which molecule you are handling, and for what. This article is informative and is not legal advice; responsibility for knowing and complying with local law rests with the buyer.
Research Use Only. All materials supplied by Condor Research are reference materials for in-vitro and laboratory research only — not for human or veterinary use, and not for diagnostic or therapeutic application. Nothing above is legal or medical advice. Supplied by Atrio Sciences s.r.o. (IČO 57 669 651), Hornočermánska 1556/76, 949 01 Nitra, Slovakia. — Condor Research · Scientific desk.
- Legality is not a property of the molecule; it depends on the intended use — supplement, medicine, or research reagent — and the three frames are governed by entirely different EU law.
- Nicotinamide riboside (NR) chloride is an authorised novel food: Commission Implementing Regulation (EU) 2020/16 added it to the Union list, permitting up to 300 mg/day in food supplements for the general adult population.
- NMN (β-nicotinamide mononucleotide), a different NAD+ precursor, is treated as a novel food but is NOT authorised — applications remain ongoing, so it cannot lawfully be marketed as an EU food supplement at present.
- NAD+ itself, the intact coenzyme, is neither an authorised novel food nor an approved medicine; Condor Research supplies it strictly as a Research Use Only reference material, not for human or veterinary use.
- The EU Novel Food framework (Regulation (EU) 2015/2283) requires pre-market authorisation; a research reagent sits outside the food regime entirely because it is not placed on the market for human consumption.
- Human clinical evidence on NAD+ precursors exists but is early and inconsistent; this article reports what studies observed and is informative only, not legal or medical advice.
Is NAD+ legal to buy in Europe?
It depends on what you mean by "NAD+." Nicotinamide riboside (NR) chloride — a NAD+ precursor — is an authorised novel food and may be sold in food supplements for adults at up to 300 mg/day under Commission Implementing Regulation (EU) 2020/16. NMN, another precursor, is treated as a novel food but is not authorised, so it cannot lawfully be marketed as an EU food supplement at present. NAD+ itself, the intact coenzyme, is supplied by Condor Research only as a Research Use Only reference material — not as a food, supplement, or medicine. None of this is legal advice; check the rules in your own jurisdiction.
Is NMN banned in the EU?
"Banned" is the wrong word. NMN is treated as a novel food, which means it requires pre-market authorisation under Regulation (EU) 2015/2283 before it can be sold as a food or supplement. As of writing, NMN is not on the EU Union list of authorised novel foods and applications are still ongoing — so it has not cleared the regulatory gate as a food, rather than being prohibited as a substance. Its status as a research reagent is a separate question from its food status.
What is the difference between NAD+ as a supplement and NAD+ for research use?
A supplement is a food placed on the market for human consumption and is governed by EU food law, including the Novel Food framework. A research-use-only (RUO) reference material is sold for in-vitro and laboratory work and is, by definition, not placed on the market for human consumption — which is precisely why it sits outside the food and medicines regimes. Condor Research supplies NAD+ as an RUO reagent only.
Is NAD+ an approved medicine in Europe?
No. NAD+ has not been reviewed or approved as a medicinal product by the European Medicines Agency or by EU member states. Because it carries no marketing authorisation, there is no lawful route to supply or use it as a medicine in the Union. Condor Research does not present it as a medicine.
Does Condor Research sell NAD+ as a supplement?
No. The NAD+ offered by Condor Research is a characterised research reference material supplied strictly Research Use Only — not a food, not a food supplement, and not a medicine, and not intended for human or veterinary use.